The recent warning from Novartis's CEO signals that the pharmaceutical industry is approaching a critical juncture regarding U.S. drug pricing.
CEO Vas Narasimhan pointed to an 18-month window where the "reality" of the Trump administration's pricing policies will truly set in. This isn't about new announcements; it's about when existing policies start to have a tangible financial impact, specifically from late 2026 into 2027. The clock is ticking toward a period of significant change.
So, what's driving this? It's a combination of three major initiatives. First is the ongoing Medicare Drug Price Negotiation Program, where the government directly negotiates a "Maximum Fair Price" (MFP) for some of the most expensive drugs. The second wave of these prices takes effect in January 2027. Second are the "Most-Favored Nation" (MFN) deals, where the administration has secured voluntary agreements from numerous drugmakers to align U.S. prices with the lowest prices in other developed nations. Third, and perhaps most impactful, are two new proposed models called GLOBE and GUARD. These are designed to implement MFN-style pricing across a wider range of drugs in Medicare Part B and Part D, with launches scheduled for October 2026 and January 2027, respectively.
This pressure didn't appear overnight, though. The groundwork was laid starting with a May 2025 Executive Order from President Trump. This was followed by letters demanding price cuts, which led to a series of "voluntary" MFN deals throughout late 2025. Then, in December 2025, the administration officially proposed the GLOBE and GUARD models, setting the 18-month countdown in motion that the Novartis CEO is now highlighting.
You might wonder why pharmaceutical stocks, including Novartis, have performed so well if these pricing pressures are so severe. So far, investors seem to have focused more on the positive optics of deals and current sales, rather than the future financial bite. However, valuations are now at a high point. For example, Novartis's P/E ratio has been trading above its historical average. This suggests that stock prices may not fully account for the potential drop in revenue and profits once these new pricing rules become reality.
The CEO's warning serves as a clear reminder that the conversation is shifting from policy debates to real-world financial consequences. The next 18 months will be a crucial period for the entire pharmaceutical sector as companies and investors alike must prepare for a new era of drug pricing in the United States.
- Glossary:
- Most-Favored Nation (MFN) Pricing: A policy requiring drug prices in the U.S. not to exceed the lowest price in a group of other developed countries.
- Medicare: The U.S. federal health insurance program for people aged 65 or older and some younger people with disabilities.
- P/E Ratio (Price-to-Earnings Ratio): A valuation metric that compares a company's stock price to its earnings per share, indicating how much investors are willing to pay for each dollar of earnings.